BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Deulumateperone readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Deulumateperone\, from ClinicalTrials.gov
  estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06480383-708@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06480383)
DESCRIPTION:Deulumateperone\, phase 2\, Generalized Anxiety Disorder.\nStud
 y: Study of ITI-1284 as an Adjunctive Treatment in Patients With Generaliz
 ed Anxiety Disorder\nEstimated primary completion: 16 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06480383
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701903-708@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20271014
DTEND;VALUE=DATE:20271015
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06701903)
DESCRIPTION:Deulumateperone\, phase 2\, Generalized Anxiety Disorder.\nStud
 y: Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized
  Anxiety Disorder\nEstimated primary completion: 14 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06701903
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651567-708@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06651567)
DESCRIPTION:Deulumateperone\, phase 2\, Alzheimer's Disease Agitation.\nStu
 dy: A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment
  of Agitation Associated With Alzheimer's Dementia\nEstimated primary comp
 letion: 28 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/deulumateperone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06651567
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540833-708@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06540833)
DESCRIPTION:Deulumateperone\, phase 2\, Alzheimer's Disease.\nStudy: A Stud
 y to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psycho
 sis Associated With Alzheimer's Disease\nEstimated primary completion: 30 
 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/deulu
 mateperone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06540833
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807865-708@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20300218
DTEND;VALUE=DATE:20300219
SUMMARY:Deulumateperone: Phase 3 readout est. (NCT07807865)
DESCRIPTION:Deulumateperone\, phase 3\, Generalized Anxiety Disorder.\nStud
 y: A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as 
 an Additional Treatment in Participants With Generalized Anxiety Disorder 
 (GAD)\nEstimated primary completion: 18 February 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/deulumateperone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07807865
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856420-708@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20300920
DTEND;VALUE=DATE:20300921
SUMMARY:Deulumateperone: Phase 3 readout est. (NCT07856420)
DESCRIPTION:Deulumateperone\, phase 3\, Generalized Anxiety Disorder.\nStud
 y: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Partic
 ipants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Resp
 onse to GAD Treatment\nEstimated primary completion: 20 September 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07856420
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
